Activity Overview
This online, on-demand virtual symposium brings together renowned experts in HR+/HER2– metastatic breast cancer (MBC). In this educational program, these experts discuss current treatment options for HR+/HER2– MBC across the continuum from endocrine-sensitive to endocrine-resistant disease. Topics include pivotal data from clinical trials in the first-line and recurrent settings, biomarker testing, sequencing considerations, and how emerging data may further impact current treatment paradigms.
This educational activity is an archive of the live symposium held on March 5, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, oncology nurses, advanced practice professionals, pathologists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate recent clinical trial data supporting novel therapies and combinations for HR+/HER2– metastatic breast cancer (MBC)
- Apply practical strategies for tailoring first-line and subsequent therapy choices based on patient, disease, and biomarker characteristics in HR+/HER2– MBC
- Implement streamlined strategies for monitoring and mitigating class-specific toxicities of targeted therapies in HR+/HER2– MBC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here